Comparative growth performance of backgrounded beef heifers treated with an injectable fixed-dose combination (0.2 mg/kg doramectin + 6.0 mg/kg levamisole hydrochloride) or single-active (0.2 mg/kg ivermectin) endectocide.

Gastrointestinal nematodes (GINs) can negatively impact all production classes of cattle, particularly growing cattle. A global decline in efficacy of broad-spectrum single-active anthelmintics requires alternative GIN control methods without the aid of novel drug classes. Here, we present a new fixed-dose combination injectable (FDCI) endectocide for cattle that combines doramectin (5 mg/ml) and levamisole hydrochloride (150 mg/ml). A 56-day comparative performance confinement backgrounding trial was conducted in stocker beef heifers (n = 1548) with confirmed GIN infections to (1) compare the Day 14 post-treatment effectiveness of the new FDCI endectocide to pen mates treated with the injectable single-active endectocide ivermectin, as evidenced by fecal egg counts (FECs) conducted for a randomly selected subset (10%) of both treatment groups, and (2) determine if the greater GIN control by the FDCI evidenced in the subsample improved growth performance in all FDCI-treated heifers. Heifers were procured in four cohorts, with a 10-week timeframe between enrollment of the first and last cohort. Treatment groups were comingled within dirt-floor pens (n = 31; 7-8 per cohort) and offered a standard backgrounding diet ad libitum for the study duration. Heifers with enrollment FEC ≥ 30 eggs per gram (EPG) were randomly allocated to receive the FDCI (n = 773) or ivermectin (n = 775) on Day 0. Day 0 FECs conducted on 10% of enrolled heifers (FDCI, n = 78; ivermectin, n = 79) were not different between treatment groups (p = 0.491). Day 14 FECs for the same heifers were reduced compared to Day 0 within each treatment group. Heifers given the FDCI had lower Day 14 AM FECs and higher FEC reduction test (FECRT) result (0.07 EPG; 0.999) than ivermectin-treated heifers (21.58 EPG; FECRT = 0.850). Mean body weight (BW) was not different between treatment groups on Day 0 (p = 0.2762) and Day 14 (p = 0.2010) but was significantly greater (p = 0.0007) for FDCI-treated heifers compared to ivermectin-treated heifers on Day 56. Compared to ivermectin-treated heifers, overall average daily gain from all evaluation periods (Day 0-14, Day 14-56, and Day 0-56) was greater (p ≤ 0.0052) in FDCI-treated heifers, and FDCI-treated heifers had 4.223 kg greater total weight gain over the 56-day study. The FDCI (0.2 mg/kg doramectin + 6.0 mg/kg levamisole hydrochloride) was highly effective in reducing GIN infections and thus promoted improved growth performance in beef heifers over a 56-day backgrounding period.

Influence of weaning strategy on behavior, humoral indicators of stress, growth, and carcass characteristics.

Weaning is one of the most stressful events a calf experiences in our current beef production system. Its effects may include reduced feed intake, increased activity, slower growth, and increased susceptibility to disease. This study was designed to evaluate weaning after a 7-d placement of nose flaps at 7 mo (N, n = 40) and delaying weaning by 49 d relative to 7-mo weaning (D, n = 39) as alternatives to the industry standard; abrupt weaning at 7 mo of age (A, n = 39). The 4-yr trial utilized Angus and Angus X Senepol steer calves. Calves were randomly assigned to weaning strategy after being stratified by dam parity (heifer/cow), hair coat phenotype (normal/slick), and body weight. Behavioral observations were made on five steers per strategy group per year over the weeks surrounding weaning. Activity levels were determined by accelerometers worn on neck collars. Blood samples were obtained from the observed cattle during the last 2 yr to determine haptoglobin and cortisol concentration. Once weaned, the steers were followed through finishing and carcass characteristics obtained at harvest. Twelve of 38 steers in the N group had sores in their nostrils from the nose flaps when the flaps were removed at weaning of A/N (237 ± 3 d of age). The A and D calves were more active than N calves in the first 2 to 3 d after weaning but settled down to similar activity levels to N by the day 4. The A and D groups were more vocal than N during the same time frame. Cortisol and haptoglobin remained within normal reference ranges. Average daily body weight gain (ADG) was greater for D than A, who in turn had greater ADG than N during the first 42 d after A and N calves were weaned (0.69, 0.54, and 0.37 kg/d for D, A, and N, respectively; P < 0.01). All treatment groups graded Low Choice at harvest and exhibited similar efficiency of gain during growth and finishing (P > 0.2). Based on ADG during the 42 d after weaning, we recommend delaying weaning when available pasture and cow body condition support this strategy. When conditions do not permit delayed weaning, abrupt weaning may be the next viable option based on animal welfare concerns and increased handling to place and remove the flaps. Nose flaps reduced vocalization at weaning but resulted in less postweaning ADG. Based on our data, we suggest that abrupt weaning under the conditions of this study, is less stressful than we perceive it to be, based on calf behavior.

A two-injection prostaglandin F2α presynchronization treatment decreases pregnancy rates of cycling replacement beef heifers.

Improving artificial insemination (AI) pregnancy rates in replacement heifers improves the genetic advancement within a herd. Heifers that have completed at least three estrous cycles prior to breeding have greater pregnancy rates compared to acyclic females. Therefore, it was hypothesized that a presynchronization treatment program consisting of two injections of prostaglandin F2α (PGF2α) prior to the start of the CO-Synch + 5 d CIDR protocol would initiate earlier attainment of puberty and more estrous cycles prior to AI, thus increasing AI pregnancy rates. All heifers were managed the same at two locations over the course of 2 yr. Heifers were randomly assigned to receive either the two-injection PGF2α presynchronization treatment (PreSynch; n = 105) or no presynchronization (Control; n = 106) prior to the start of estrous synchronization. On the first day of the trial, reproductive tract scores (RTSs), pelvic areas, body condition scores, and weights were collected on all heifers. All heifers were synchronized with the CO-Synch + 5 d CIDR protocol and fixed-time artificially inseminated with semen from a bull of known fertility. Blood samples were collected three consecutive times at 7 d intervals starting 45 d prior to estrous synchronization to determine the onset of puberty via analyzing progesterone concentrations. Pregnancy status to AI was assessed using ultrasonography diagnosis at approximately 30 and 60 d post insemination. Data were analyzed using PROC MIXED of SAS and reported as least square mean. The PreSynch treatment decreased AI pregnancy rates (52.2% vs. 38.1 ± 6.3% for Control vs. PreSynch, respectively; P = 0.06) and did not result in earlier attainment of puberty in beef heifers (P > 0.05). The PreSynch treatment did not impact pregnancy rates in heifers with an RTS of 3 or 4 (P > 0.05). However, PreSynch heifers with an RTS of 5 had decreased pregnancy rates (68.3% vs. 46.9 ± 10.1% for Control vs. PreSynch, respectively; P < 0.05). Finally, PreSynch heifers with increased body condition of 6 had decreased pregnancy rates when compared to Control heifers (37.5% vs. 62.5 ± 11.6%, respectively; P < 0.05). On the basis of these data, implementation of heifer breeding soundness examination at least 3 wk prior to the start of the breeding season may be beneficial for selecting replacement females; however, presynchronization with prostaglandins immediately prior to estrous synchronization will negatively affect AI pregnancy rates in cycling pubertal heifers.

An MRA study of vascular stenosis in a pig model using CH3-DTPA-Gd (NMS60) and Gd-DTPA.

PURPOSE: This study used an experimental arterial stenosis model in pigs to evaluate the utility of a new medium-weight MRI contrast agent, NMS60 (a synthetic oligomeric Gd complex containing three Gd(3+) atoms, molecular weight of 2158 Da) compared to Gd-DTPA for contrast-enhanced MRA. MATERIALS AND METHODS: We used six male white hybrid pigs. Under anesthesia, one femoral artery was exposed and an inflatable cuff placed around it. The cuff was tightened around the vessel until 80-90% stenosis was achieved using digital subtraction angiography as a guide. Animals were then immediately transferred to the MRI scanner and images acquired pre- and postcontrast injection (0.1 or 0.2 mmol Gd/kg Gd-DTPA or NMS60, as a rapid bolus) using high-resolution and dynamic MRA. RESULTS: The dynamic MRA scans acquired during contrast bolus injection clearly showed the stenosed femoral artery as a segment of close to zero enhancement during the arterial phase of the bolus transit, while on the high-resolution scans the stenosis was difficult to detect due to venous signal contamination. The signal-to-noise at peak enhancement on the dynamic scans was significantly greater with 0.1 mmol Gd/kg NMS60 compared to 0.1 mmol Gd/kg Gd-DTPA (14.6 vs. 9.9, P < .05) and not significantly greater than 0.2 mmol Gd/kg (14.6 vs. 12.8). DISCUSSION AND CONCLUSION: This new medium-weight contrast agent demonstrated significantly greater enhancement than Gd-DTPA and may be valuable to aid detection of vascular stenosis in humans.

Evaluation of a Serpens species bacterin for treatment of digital dermatitis in dairy cattle.

Digital dermatitis is a major cause of lameness in many dairy herds and represents a detriment to milk production, reproductive efficiency, productive lifespan and welfare. The purpose of this study was to evaluate the therapeutic use of a Serpens species bacterin in a dairy herd known to have a significant prevalence of lameness due to digital dermatitis. Seventy-six mature lactating Holsteins were enrolled in this study. Group 1 (n=38) received three injections of a Serpens species bacterin at four-week intervals (weeks 0, 4, and 8) while group 2 (n=38) received only adjuvant. Blood samples were obtained prior to the first injection at week 0 and again at week 12 to evaluate antibody responses. Locomotion and digital dermatitis lesion measurements were performed at weeks 0, 12 and 18. Although Serpens-associated antibody titers increased from week 0 to 12 in vaccinated cows; the prevalence of digital dermatitis, the percentage of cows identified as clinically lame and the average width of digital dermatitis lesions did not differ from week 0 to 12 or from week 0 to 18 between groups. The results of this study indicate a lack of any clinical efficacy associated with vaccination in this herd, although inoculation with the bacterin did stimulate a measurable antibody response.

Efficacy of amprolium for the treatment of pathogenic Eimeria species in Boer goat kids.

This study evaluated the efficacy of two different doses of amprolium in goats heavily infected with pathogenic Eimeria species. Forty Boer goat kids ranging from 3 to 5 months of age with naturally occurring coccidiosis were randomly divided into 2 groups and treated orally with amprolium at doses of 10mg/kg daily for 5 days (n=20) or 50mg/kg daily for 5 days (n=20). The Eimeria oocyst per gram concentrations were significantly reduced on day 7 in the kids that received amprolium at 50mg/kg, however oocyst concentrations were not significantly reduced in goats that received the 10mg/kg dose. Out of 100 Eimeria oocysts identified from a pooled fecal sample, E. christenseni was the most frequently identified (52%) coccidial species present. The results of this trial indicate that amprolium can be an effective treatment for pathogenic Eimeria species in goat kids, however higher and extralabel doses (50mg/kg) should be used.